| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/ploscb/PrinzVAC16 |
| P356 | DOI | 10.1371/JOURNAL.PCBI.1005111 |
| P3181 | OpenCitations bibliographic resource ID | 3326412 |
| P932 | PMC publication ID | 5038975 |
| P698 | PubMed publication ID | 27673331 |
| P2093 | author name string | Ingo Vogt | |
| Gianluca Adornetto | |||
| Jeanette Prinz | |||
| Mónica Campillos | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity | Q24317396 | ||
| Anabolic effects of oxandrolone after severe burn | Q24541783 | ||
| STRING: known and predicted protein-protein associations, integrated and transferred across organisms | Q24558597 | ||
| Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective | Q24595403 | ||
| The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored | Q24607390 | ||
| DrugBank 3.0: a comprehensive resource for 'omics' research on drugs | Q24612505 | ||
| Selective enzyme purification by affinity chromatography | Q24644794 | ||
| Predicting new molecular targets for known drugs | Q24649687 | ||
| The Mammalian Phenotype Ontology as a tool for annotating, analyzing and comparing phenotypic information | Q24805716 | ||
| Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs | Q27499827 | ||
| PharmGKB: a logical home for knowledge relating genotype to drug response phenotype | Q28295504 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer | Q28377995 | ||
| Drug-induced regulation of target expression | Q28475443 | ||
| Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs | Q28478103 | ||
| A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer | Q28485246 | ||
| Signaling role of prokineticin 2 on the estrous cycle of female mice | Q28540891 | ||
| The druggable genome | Q29547361 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program | Q29614363 | ||
| Drug target identification using side-effect similarity | Q29615103 | ||
| ROCR: visualizing classifier performance in R | Q29615821 | ||
| STITCH 3: zooming in on protein-chemical interactions | Q30002340 | ||
| Systematic identification of proteins that elicit drug side effects | Q30002377 | ||
| Improving disease gene prioritization by comparing the semantic similarity of phenotypes in mice with those of human diseases | Q31068610 | ||
| UMLS language and vocabulary tools | Q33196881 | ||
| Improved human disease candidate gene prioritization using mouse phenotype | Q33302863 | ||
| Target profiling of small molecules by chemical proteomics | Q33494810 | ||
| Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1. | Q48964677 | ||
| Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. | Q51662922 | ||
| The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty. | Q52398746 | ||
| Market watch: Sales of biologics to show robust growth through to 2013. | Q53492495 | ||
| Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty. | Q55067006 | ||
| Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations | Q87880616 | ||
| The medical dictionary for regulatory activities (MedDRA). | Q33542532 | ||
| In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project | Q33789756 | ||
| Functional rescue of Kallmann syndrome-associated prokineticin receptor 2 (PKR2) mutants deficient in trafficking | Q34075966 | ||
| Rapid actions of steroid receptors in cellular signaling pathways. | Q34135517 | ||
| Anabolic steroid abuse and dependence | Q34149477 | ||
| Pharmacogenomics--drug disposition, drug targets, and side effects | Q34175616 | ||
| Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy | Q34215250 | ||
| Polypharmacology: drug discovery for the future | Q34319906 | ||
| Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications | Q34501447 | ||
| Target identification and mechanism of action in chemical biology and drug discovery | Q34626974 | ||
| The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease | Q34865360 | ||
| Stategic trends in the drug industry | Q35111514 | ||
| Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome | Q35237812 | ||
| Genomics and drug response | Q35252277 | ||
| Large-scale prediction and testing of drug activity on side-effect targets | Q36059863 | ||
| Systematic analysis of gene properties influencing organ system phenotypes in mammalian perturbations | Q36171779 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Post-translational modifications in the context of therapeutic proteins | Q36620451 | ||
| Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction | Q36662865 | ||
| A three-hybrid system for detecting small ligand-protein receptor interactions | Q36684250 | ||
| Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. | Q36938312 | ||
| Target deconvolution strategies in drug discovery | Q36961595 | ||
| A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure | Q37401858 | ||
| Mouse model phenotypes provide information about human drug targets | Q37601567 | ||
| The expanding universe of p53 targets | Q37602507 | ||
| Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution | Q38089202 | ||
| New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris. | Q38092339 | ||
| In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme | Q38200703 | ||
| The Mouse Genome Database genotypes::phenotypes | Q43122475 | ||
| Knockouts model the 100 best-selling drugs--will they model the next 100? | Q43436501 | ||
| Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia | Q43561584 | ||
| Phen-Gen: combining phenotype and genotype to analyze rare disorders | Q43870817 | ||
| Triazine compounds as antagonists at Bv8-prokineticin receptors | Q46249141 | ||
| HitPick: a web server for hit identification and target prediction of chemical screenings | Q47884285 | ||
| Oxandrolone disposition and metabolism in man | Q47974467 | ||
| FSH receptor in vitro modulation by testosterone and hCG in human luteinized granulosa cells. | Q48640019 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e1005111 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | PLOS Computational Biology | Q2635829 |
| P1476 | title | A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug Effects | |
| P478 | volume | 12 |
Search more.